Allopurinol Improves Myocardial Efficiency in Patients With Idiopathic Dilated Cardiomyopathy

DOI Web Site 被引用文献18件
  • Thomas P. Cappola
    From the Department of Medicine, Division of Cardiology, Johns Hopkins Medical Institutions, Baltimore, Md.
  • David A. Kass
    From the Department of Medicine, Division of Cardiology, Johns Hopkins Medical Institutions, Baltimore, Md.
  • Gregory S. Nelson
    From the Department of Medicine, Division of Cardiology, Johns Hopkins Medical Institutions, Baltimore, Md.
  • Ronald D. Berger
    From the Department of Medicine, Division of Cardiology, Johns Hopkins Medical Institutions, Baltimore, Md.
  • Gisele O. Rosas
    From the Department of Medicine, Division of Cardiology, Johns Hopkins Medical Institutions, Baltimore, Md.
  • Zoulficar A. Kobeissi
    From the Department of Medicine, Division of Cardiology, Johns Hopkins Medical Institutions, Baltimore, Md.
  • Eduardo Marbán
    From the Department of Medicine, Division of Cardiology, Johns Hopkins Medical Institutions, Baltimore, Md.
  • Joshua M. Hare
    From the Department of Medicine, Division of Cardiology, Johns Hopkins Medical Institutions, Baltimore, Md.

抄録

<jats:p> <jats:bold> <jats:italic> <jats:bold> <jats:italic>Background</jats:italic> </jats:bold> </jats:italic> </jats:bold> Dilated cardiomyopathy is characterized by an imbalance between left ventricular performance and myocardial energy consumption. Experimental models suggest that oxidative stress resulting from increased xanthine oxidase (XO) activity contributes to this imbalance. Accordingly, we hypothesized that XO inhibition with intracoronary allopurinol improves left ventricular efficiency in patients with idiopathic dilated cardiomyopathy. </jats:p> <jats:p> <jats:bold> <jats:italic> <jats:bold> <jats:italic>Methods and Results</jats:italic> </jats:bold> </jats:italic> </jats:bold> Patients (n=9; ejection fraction, 29±3%) were instrumented to assess myocardial oxygen consumption (MV̇ <jats:sc>o</jats:sc> <jats:sub>2</jats:sub> ), peak rate of rise of left ventricular pressure (dP/dt <jats:sub>max</jats:sub> ), stroke work (SW), and efficiency (dP/dt <jats:sub>max</jats:sub> /MV̇ <jats:sc>o</jats:sc> <jats:sub>2</jats:sub> and SW/MV̇ <jats:sc>o</jats:sc> <jats:sub>2</jats:sub> ) at baseline and after sequential infusions of intracoronary allopurinol (0.5, 1.0, and 1.5 mg/min, each for 15 minutes). Allopurinol caused a significant decrease in MV̇ <jats:sc>o</jats:sc> <jats:sub>2</jats:sub> (peak effect, −16±5%; <jats:italic>P</jats:italic> <0.01; n=9) with no parallel decrease in dP/dt <jats:sub>max</jats:sub> or SW and no change in ventricular load. The net result was a substantial improvement in myocardial efficiency (peak effects: dP/dt <jats:sub>max</jats:sub> /MV̇ <jats:sc>o</jats:sc> <jats:sub>2</jats:sub> , 22±9%, n=9; SW/MV̇ <jats:sc>o</jats:sc> <jats:sub>2</jats:sub> , 40±17%, n=6; both <jats:italic>P</jats:italic> <0.05). These effects were apparent despite concomitant treatment with standard heart failure therapy, including ACE inhibitors and β-blockers. XO and its parent enzyme xanthine dehydrogenase were more abundant in failing explanted human myocardium on immunoblot. </jats:p> <jats:p> <jats:bold> <jats:italic> <jats:bold> <jats:italic>Conclusions</jats:italic> </jats:bold> </jats:italic> </jats:bold> These findings indicate that XO activity may contribute to abnormal energy metabolism in human cardiomyopathy. By reversing the energetic inefficiency of the failing heart, pharmacological XO inhibition represents a potential novel therapeutic strategy for the treatment of human heart failure. </jats:p>

収録刊行物

  • Circulation

    Circulation 104 (20), 2407-2411, 2001-11-13

    Ovid Technologies (Wolters Kluwer Health)

被引用文献 (18)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ